SCHEMBL6283416

SCHEMBL6283416

O=[C]COc1cccc2cnccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.57
HTT P42858 1/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2D6 P10635 2/20 0.45
LMNA P02545 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPKAPK2 P49137 1/20 0.45
NR3C1 P04150 3/20 0.45
CACNA2D1 P54289 7/20 0.44
GPBAR1 Q8TDU6 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRB3 P13945 1/20 0.41
PRKD3 O94806 1/20 0.41
PRKCG P05129 1/20 0.41
PRKCB P05771 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2121728 0.80 KDM4E (0.56) KCNA3CYP1A2CYP2C19KDM4E
SCHEMBL21178262 0.79 KCNA3 (0.50) KCNA3HTTCYP3A4CYP2D6LMNA
SCHEMBL11144866 0.79 KCNA3 (0.61) KCNA3HTTCYP3A4CYP2D6LMNA
SCHEMBL94801 0.79 KCNA3 (0.61) KCNA3HTTCYP3A4CYP2D6LMNA
SCHEMBL14251166 0.79 KCNA3 (0.61) KCNA3HTTCYP3A4CYP2D6LMNA
SCHEMBL7991108 0.78 KCNA3 (0.57) KCNA3HTTCYP3A4CYP2D6LMNA
SCHEMBL7344375 0.77 KDM4E (0.67) KCNA3CYP3A4CYP2D6LMNACYP1A2
SCHEMBL4328934 0.76 KCNA3 (0.67) KCNA3HTTCYP3A4CYP2D6LMNA
SCHEMBL96699 0.76 KCNA3 (0.67) KCNA3HTTCYP3A4CYP2D6LMNA
SCHEMBL1545737 0.76 KCNA3 (0.71) KCNA3HTTCYP3A4CYP2D6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900238-B1 HIV protease inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2005-05-31 US disclosed
EP-0873519-A4 HIV PROTEASE INHIBITORS SCRIPPS RESEARCH INST (US) 2005-04-27 EP disclosed
US-6329502-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) JAPAN ENERGY CORPORATION (JP) 2001-12-11 US disclosed
US-6313094-B1 COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION JAPAN ENERGY CORPORATION (JP) 2001-11-06 US disclosed
US-6291432-B1 (R)-N-(2-METHYLBENZYL)-3-((2S, 3S)-3-(N-(2-CHROMONECARBONYL)-L-ASPARAGINYL)AMINO-2-HYDROXY-4-PHENYLBUTANO YL)-5,5-DIMETHYL-1,3-THIAZOLIDINE-4-CARBOXAMIDE CAN BE GIVEN AS A TYPICAL EXAMPLE OF THIS COMPOUND. JAPAN ENERGY CORPORATION (JP) 2001-09-18 US disclosed
EP-0490667-B1 HIV protease inhibitors JAPAN ENERGY CORP (JP) 1999-06-09 EP disclosed
EP-0900566-A1 NOVEL TRIPEPTIDE COMPOUNDS AND ANTI-AIDS DRUGS JAPAN ENERGY CORPORATION (JP) 1999-03-10 EP disclosed
EP-0873519-A1 HIV PROTEASE INHIBITORS The Scripps Research Institute (US) 1998-10-28 EP disclosed
WO-1997021100-A9 HIV PROTEASE INHIBITORS 1997-10-30 WO disclosed
WO-1997021100-A1 HIV PROTEASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 1997-06-12 WO disclosed
EP-0490667-A2 HIV protease inhibitors JAPAN ENERGY CORPORATION (JP) 1992-06-17 EP disclosed